Spotting undervalued shares, Savills & weight-loss drugs: The Companies and Markets Show
We begin with Hugh Moorhead and recent results from Savills (SVS), which were in line with expectations. Hugh and Dan unpack what divisions brought in the highest profits, a breakdown of a handful of global performances, and what the business’s valuation appears to be. Next up James Norrington joins to unpack our…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Investors' Chronicle
See all episodes →
Similar episodes from other shows
More like Investors' Chronicle →
Investing in weight-loss drugs, and why everyone’s talking about student loans
Novo Nordisk, Eli Lilly and the GLP-1 economy
Novo Nordisk hits back at copycat drugs
A New Name in Weight-Loss Drugs
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.